logo
logo

Design Pharmaceuticals Closes $5 Million Pre-Series A Round To Accelerate Commercialization Of Ultrahigh Throughput Drug Discovery Platform

Apr 12, 2022•over 3 years ago

Amount Raised

$5 Million

Round Type

pre-series a

Cambridge

Description

Design Pharmaceuticals, a company redesigning small molecule drug discovery, today announced the closing of a pre-series A round of $5 million, including an investment of $3 million from Virtus Inspire Venture Partners. The proceeds will be used to further build the company’s discovery platform and operations. Design Pharmaceuticals’ platform is based on ultrahigh-throughput technologies that biomine drug-like molecules from natural sources, such as microbiota. These molecules are then evaluated at unprecedented speed and scale on hundreds of GPCR targets simultaneously.

Company Information

Company

Design Pharmaceuticals

Location

Cambridge, Maryland, United States

About

Design Pharmaceuticals harnesses nature’s chemistry of drug-like molecules to develop breakthrough therapeutics. The company’s approach aims to redesign the process of small molecule-based drug discovery and development by using engineering-inspired biotechnologies to access these undiscovered molecules and accelerate the drug discovery process saving time and costs. The platform is based on ultrahigh-throughput technologies that biomine and test drug-like molecules from nature at unprecedented speed and scale on hundreds of GPCR targets simultaneously. Design Pharmaceuticals’ cell-free biosynthesis eliminates the inherent limitations of traditional chemistry or using platforms based on live production strains further accelerating lead compound optimization. The company’s business model aims to build a continuously growing portfolio of joint development and license agreements with pharma partners. For more information, visit www.designpharmaceuticals.com